<DOC>
	<DOCNO>NCT00459524</DOCNO>
	<brief_summary>Primary Objectives : - To compare neuropsychiatric ( NP ) neurocognitive ( NC ) symptoms assess quality life ( QOL ) old patient ( age &gt; 18 ) acute myelogenous leukemia ( AML ) high-risk myelodysplastic syndrome ( MDS ) receive different therapy , chemotherapy ( Clofarabine + ara-C ) target therapy ( PKC412 + low-dose ara-C , R115777 + low-dose ara-C , decitabine , STI + low-dose ara-C ) . - To determine whether correlation number pack red blood cell ( PRBC ) transfusion cognitive score and/or QOL .</brief_summary>
	<brief_title>Quality Life Patients With Acute Myelogenous Leukemia ( AML ) Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>You participate series neurocognitive test . For test , ask complete certain task require use hand , eye , ear . The neurocognitive test take 30 minute . You answer questionnaire disease symptom quality life . It take 30 minute complete questionnaire . You participate neurocognitive test fill questionnaires begin cancer therapy . Your interval test coincide clinic visit evaluation , approximately 1 month , 3 month , 6 month . If receive therapy , ask complete neurocognitive test baseline follow clinic visit evaluation , approximately 3 month 6 month . You may ask continue participation neurocognitive test fill questionnaire approximately every 3 month thereafter . This investigational study . About 306 patient take part study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>1 . Patients newly diagnose AML MDS . Patients fail MDS/AML therapy receive therapy may ask continue participation neurocognitive study . 2 . Patients 18 year age old . 3 . Patients see MDACC adult Leukemia clinic . Patients enroll onto therapy protocol also eligible . 4 . Patients must sign informed consent . 1 ) Not applicable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
	<keyword>Neurocognitive Function</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
	<keyword>QOL</keyword>
</DOC>